COX-2 (human, recombinant)

Cyclooxygenase 2 (COX-2) is a bifunctional enzyme that exhibits both COX and peroxidase activities and catalyzes the first step in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins.^1,2 The COX component converts arachidonic acid to the hydroperoxy endoperoxide prostaglandin G₂ (PGG₂; Item No. 17010), and the peroxidase component reduces the endoperoxide to the corresponding alcohol PGH₂ (Item No. 17020). COX-2 expression is induced by a variety of stimuli, including phorbol esters, LPS, and cytokines and is responsible for the biosynthesis of PGs under acute inflammatory conditions.³ Thus, COX-2 has been the focus of attention for the nonsteroidal anti-inflammatory drug (NSAID) development. Cayman's COX-2 (human, recombinant) contains an N-terminal hexahistidine tag and an alanine substituted for asparagine at position 580 (COX-2^N580A) that prevents glycosylation at position 580 and decreases enzyme degradation in cells.⁴

WARNING This product is not for human or veterinary use.

1. Nugteren, D.H., and Hazelhof, E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim. Biophys. Acta 326(3), 448-461 (1973).

2. Hamberg, M., and Samuelsson, B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA 70(3), 899-903 (1973).

3. Blobaum, A.L., and Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 50(7), 1425-1441 (2007).

4. Sevigny, M.B., Li, C.-F., Alas, M., et al. Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett. 580(28-29), 6533-6536 (2006).

Zhao-Yong, Y., Zhi-Fei, Z., Xiao-Bo, H., et al. Study on the effect of amicoumacin B on up-regulating bmp-2 transcription and expression in MG63 cells. Chin. J. Antibiot. 33(4), 203-205 (2008).

Beeghly-Fadiel, A., Wilson, A.J., Keene, S., et al. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. J. Ovarian Res. 11(17), (2018).

Gouveia-Figueira, S., Karlsson, J., Deplano, A., et al. Characterisation of (R)-2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: Cyclooxygenase inhibitor. PLoS One 10(9), e0139212 (2015).

Karlsson, J., and Fowler, C.J. Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen. PLoS One 9(7), e103589 (2014).

Hoobler, E.K., Warrilow, A.G., Perry, S.C., et al. Discovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy. PLoS One 8(6), e65928 (2013).